Abstract | CONTEXT: OBJECTIVE: To evaluate HER-2/neu, p53, MIB1, and ER/PR as markers in the differential diagnosis of MC, AMC, and HGIDC.Design.-Nine cases of MC, 13 cases of AMC, and 16 cases of HGIDC with prominent lymphocytic infiltrates were identified according to strict histologic criteria. All tests were performed on formalin-fixed, paraffin-embedded archival tissues. HER-2/neu gene amplification was examined by fluorescence in situ hybridization using PathVysion HER-2 DNA probes. Expression of HER-2/neu, p53, MIB1, and ER/PR was detected by immunohistochemistry. chi2 and Student t tests were applied for statistical analyses. RESULTS: None of 9 cases of MC examined had either amplification or overexpression of HER-2/neu (0%). In contrast, HER-2/neu amplification was observed in AMC (46%, P <.025) and HGIDC (56%, P <.005). All 3 categories of tumors had similar percentages of expression of p53 (78% of MC, 77% of AMC, and 69% of HGIDC) and MIB1 (89% of MC, 92% of AMC, and 94% of HGIDC). Immunostaining for ER/PR was rarely positive in either MC or AMC, and there were no significant differences of expression of ER/PR between these 2 lesions (P >.05). However, the expression rate of ER/PR (31%/44%) in HGIDC is higher than in both MC (P =.05) and AMC (P =.01). CONCLUSIONS:
Medullary carcinoma of breast is distinct from AMC and HGIDC with prominent lymphocytic infiltrates in amplification and overexpression of HER-2/neu. This difference may account for its different clinical and biological behavior, and may potentially aid in diagnosis and management of these groups of patients.
|
Authors | Ruliang Xu, Helen Feiner, Peng Li, Herman Yee, Giorgio Inghirami, Yara Delgado, Mary Ann Perle |
Journal | Archives of pathology & laboratory medicine
(Arch Pathol Lab Med)
Vol. 127
Issue 11
Pg. 1458-64
(Nov 2003)
ISSN: 1543-2165 [Electronic] United States |
PMID | 14567723
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Ki-67 Antigen
- Receptors, Estrogen
- Receptors, Progesterone
- Tumor Suppressor Protein p53
- Receptor, ErbB-2
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
- Breast Neoplasms
(genetics)
- Carcinoma, Ductal, Breast
(genetics)
- Carcinoma, Medullary
(genetics)
- Diagnosis, Differential
- Gene Amplification
(genetics)
- Gene Expression Regulation, Neoplastic
(genetics)
- Genes, erbB-2
- Genes, p53
- Humans
- Ki-67 Antigen
(biosynthesis, genetics)
- Lymphocytes, Tumor-Infiltrating
(pathology)
- Middle Aged
- Receptor, ErbB-2
(biosynthesis, genetics)
- Receptors, Estrogen
(biosynthesis, genetics)
- Receptors, Progesterone
(biosynthesis, genetics)
- Tumor Suppressor Protein p53
(biosynthesis, genetics)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|